Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
New Active Ingredient + Innovative Drug Delivery System = Business Success More
A liquid system which enables rapid transmigration of therapeutic doses of up to large molecules More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
This ORS effervescent tablet has been developed according to the latest guidelines of the WHO. We are looking for partners in Europe and in other areas to commercialize the ORS effervescent tablets More
Kortos® Cream contains anti-inflammatory-antipruritic-vasoconstrictor, astringent, antiseptic and local anesthetic in a special water repellant base. More
p38 MAP Kinase inhibitors as modulators of pro-inflammatory cytokine-expression for treatment of inflammation-related diseases like rheumatoid arthritis, inflammatory bowel disease, psoriasis, or acute coronary syndrome. More
Phytohealth Corporation: PH3 (PHN031, PHN033) - For osteoporosis and diabetic vascular complications
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
CIP-FENOFIBRATE is a novel oral formulation of Fenofibrate capsules that has been developed using new proprietary, superbioavailable drug delivery technology referred to as Lidose®. More
The University of Edinburgh has perfected a genetic engineering strategy in mouse embryonic stem cells to replace large regions of mouse chromosomal sequences (>100kb) with the corresponding human syntenic region. More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- Acute coronary syndromes
- Anemia
- Anticoagulants
- Blood clotting
- Blood composition
- Cardiovascular disorder (other)
- Cerebrovascular disorders
- Thrombotic disorders
- Treatments
- Vascular
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us